Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zunsemetinib - Aclaris Therapeutics

Next Previous
Drug Profile

Zunsemetinib - Aclaris Therapeutics

Alternative Names: ATI-450; CDD-450

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Confluence Life Sciences
  • Developer Aclaris Therapeutics; Washington University School of Medicine
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Halogenated hydrocarbons; Pyridines; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer
  • Phase I Adenocarcinoma
  • Discontinued COVID 2019 infections; Cryopyrin-associated periodic syndromes; Hidradenitis suppurativa; Psoriasis; Psoriatic arthritis; Pyoderma gangrenosum; Rheumatoid arthritis

Most Recent Events

  • 15 May 2025 Phase-I clinical trials in Adenocarcinoma (Late-stage disease, Metastatic disease, First-line therapy, Combination therapy, Inoperable/Unresectable) in USA (PO) (NCT06648434)
  • 30 Jan 2025 Phase-I/II clinical trials in HER2-negative-breast-cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT06374459)
  • 24 Oct 2024 Washington University School of Medicine plans a phase I trial for Adenocarcinoma (First line therapy, Metastatic disease, Combination therapy) in USA (PO) (NCT06648434)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top